Pharmacy Podcast Network

"The only way to change the status-quo is to get off your ass and change it." 

Dave Marley, Marley Drug: 

It's not easy but it's possible to fight the 3 largest PBMs in your local community with your pharmacy services. Listen into this podcast & share with other pharmacy owners for several ideas on beating the PBMs in Community Pharmacy. 

Thank you ApproRx & P.U.T.T. for sponsoring this podcast webinar.  

Here's the back-drop information on Marley Drug & Medicure: 

https://www.medicure.com/about 

Work with Medicure today: 

Neal Owens [email protected] 

IN A RARE MOVE, A DRUG MANUFACTURER WILL BYPASS THE TRADITIONAL APPROACH AND PROVIDE ACCESS TO AFFORDABLE MEDICATIONS ACROSS THE UNITED STATES VIA MARLEY DRUG’S ESTABLISHED MAIL ORDER PHARMACY.  

With licensing to deliver prescription drugs to all 50 states, Washington D.C. and Puerto Rico, and with an established vision to deliver low cost generic medications, Marley Drug Pharmacy was the natural choice for like-minded Canadian drug manufacturer, Medicure Inc., to further expand distribution of its products within the United States, included its branded statin, Zypitamag® (pitavastatin).  

The acquisition allows Medicureto bypass wholesalers and pharmacy benefit managers (PBMs), in an effort to reduce consumer drug costs and provide patients across the U.S. easier access to Zypitamag®, which was extremely difficult for patients and physicians to access because of restrictions and high co-pays dictated by insurers and PBMs. Through Marley Drug Pharmacy, Medicurecan now deliver Zypitamag® to patients in every U.S. state without customers needing to use their insurance, or worry if the prescription will be covered. Medicurecan also provide Zypitamag® at a lower price overall, and a fraction of the cash price of a leading branded statin Livalo® (pitavastatin). As a manufacturer, Medicureintends to provide other branded medications using a similar approach, in addition to extremely low cost generic medications.

“It’s a perfect and responsible transition for Marley Drug,” said Dr. David Marley, CEO & President of Marley Drug. “Medicureshares our moral mission to cut drug costs for consumers. Since 2012 we have offered Marley’s Extended Supply Generic Drug Program, which was designed to battle the skyrocketing costs of name-brand drugs, and offer patients affordable alternatives, without increasing co-pays or limiting access to popular generics.  We worked hard to acquire permits in every state.  Now Medicurecan offer Zypitamag® from coast to coast at a fraction of the cost, without the hassle of PBMs and wholesalers.” 

“Medicure and Marley Drug have the same vision. We want to deliver safe, efficacious and cost-effective medicines that benefit patients and healthcare providers. Our goal is to increase patient access to Zypitamag® while keeping the process and pricing as simple as possible. Through Marley Drug Pharmacy, we can now provide these benefits regardless of insurance or location,” said Dr. Albert Friesen, CEO of Medicure. “There will be no changes to the hours, location or to the great staff and customer service that Marley has built, and look to hire more staff as business grows. Dave Marley will remain a member of the leadership team, and we want Marley Drug to remain a trusted business within the community, and hopefully, this is a game-changing approach that gains attention nationwide.”

Thanks RxSafe for Sponsoring this episode: 

RxSafe.com 

See omnystudio.com/listener for privacy information.

In this episode we are joined by a very special guest, Jill Murphy from Pharmacy Focus Podcast, to discuss some old-timey medical treatments and how they've evolved over time. From the Iron Lung to the Clap, we hope you enjoy these four antiquated medical treatments.

This is NOT your physician's podcast. Hosts Shane Garrettson and Cal Vandergrift dive into the pharmacy world with fun, interesting, and downright weird topics!

Tune in for NEW episodes, available on Spotify, Apple, Anchor, and more! Check out our Facebook, Twitter, and Instagram pages at Let's Pharmonize to view videos and images relevant to every episode! If you have any questions, comments, or even corrections, e-mail us at [email protected].

PLEASE READ: Shane, Cal and Jill are NOT medical professionals. DO NOT USE the information presented in this podcast to aid in your own personal health or medicinal benefit. This is a light-hearted podcast that should not be taken with the same seriousness as your own personal health,

A special thanks to Kelly Kerr for creating the music used in the intro and outro.

See omnystudio.com/listener for privacy information.

In this episode we are joined by a very special guest, Jill Murphy from Pharmacy Focus Podcast, to discuss some old-timey medical treatments and how they've evolved over time. From the Iron Lung to the Clap, we hope you enjoy these four antiquated medical treatments.

This is NOT your physician's podcast. Hosts Shane Garrettson and Cal Vandergrift dive into the pharmacy world with fun, interesting, and downright weird topics!

Tune in for NEW episodes, available on Spotify, Apple, Anchor, and more! Check out our Facebook, Twitter, and Instagram pages at Let's Pharmonize to view videos and images relevant to every episode! If you have any questions, comments, or even corrections, e-mail us at [email protected].

PLEASE READ: Shane, Cal and Jill are NOT medical professionals. DO NOT USE the information presented in this podcast to aid in your own personal health or medicinal benefit. This is a light-hearted podcast that should not be taken with the same seriousness as your own personal health,

A special thanks to Kelly Kerr for creating the music used in the intro and outro.

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices

March Madness inspired us, and our audience has waited long enough. What better time, than during a pandemic, to dive into “OPIOID MADNESS” and crown “The Greatest Opioid of All Time”!!!

In this episode of the “PAIN POD”, Mark “Pain Guy” Garofoli will continue the conversation from Opioid Madness Part 1, the opioid bracketology, or perhaps an “Opioidology”, but definitely a whole bunch of “Opioid Madness”. The battle of poppy versus poppy, and of course a bunch of man-made opioid opponents as well. Cool names and fancy formulations only get one so far, and we simply have no room for bias, thus pharmacology will rule as law of the land, to ultimately crown, “THE GREATEST OPIOID OF ALL TIME”.

The blood thirsty, constipating, yet definitely not sedating championship opioid brawl continues. One opioid, an opioid of all opioids, will remain standing atop the mountain of Mu, declaring its victory over all other opioids from all lands near and far. Which opioid will it be? The PAIN POD crowns the champ!

See omnystudio.com/listener for privacy information.

March Madness inspired us, and our audience has waited long enough. What better time, than during a pandemic, to dive into “OPIOID MADNESS” and crown “The Greatest Opioid of All Time”!!!

In this episode of the “PAIN POD”, Mark “Pain Guy” Garofoli will continue the conversation from Opioid Madness Part 1, the opioid bracketology, or perhaps an “Opioidology”, but definitely a whole bunch of “Opioid Madness”. The battle of poppy versus poppy, and of course a bunch of man-made opioid opponents as well. Cool names and fancy formulations only get one so far, and we simply have no room for bias, thus pharmacology will rule as law of the land, to ultimately crown, “THE GREATEST OPIOID OF ALL TIME”.

The blood thirsty, constipating, yet definitely not sedating championship opioid brawl continues. One opioid, an opioid of all opioids, will remain standing atop the mountain of Mu, declaring its victory over all other opioids from all lands near and far. Which opioid will it be? The PAIN POD crowns the champ!

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices

CDC Proclaims Racism Public Health Crisis, Calls for Health Equity

A new mandate out of the Centers for Disease Control & Prevention has asserted systemic racism as a public health crisis, a step the agency says will build the foundation to improve health equity.

The statement from CDC’s director Rochelle P. Walensky, MD, MPH, acknowledged the racial health disparities seen in traditionally marginalized communities, including the Black, Latinx, and American Indian/Alaska Native (AI/AN) populations.

“Yet, the disparities seen over the past year were not a result of COVID-19,” Walensky said in the written statement. “Instead, the pandemic illuminated inequities that have existed for generations and revealed for all of America a known, but often unaddressed, epidemic impacting public health: racism.”

Guests: 

Yele Aluko, MD, MBA

Chief Medical Officer

EY Americas

Dr. Yele Aluko is the chief medical officer in EY Americas Business Consulting Health Sector. He is a proven physician executive and leader, with 25 years of clinical and administrative health system experience prior to joining Ernst & Young LLP in 2016. He advises health system clients on strategy, business and clinical operations providing C-Suite executives insight on health industry megatrends and enterprise growth opportunities. He is a member of the EY COVID-19 Pandemic Response Team where he advises EY leadership on return-to-workplace strategies that prioritize the health and safety of its employees. As a member of the EY COVID-19 Enterprise Resiliency Team, he provides client insight on return-to-work strategies and solutions designed to preserve workforce well-being and safety during and in the aftermath of COVID-19. He is a leader in the development of the EY Point of View on Health Equity and has designed solutions for clients seeking competencies relevant to elimination of health disparities and achieving health equity.

As chief medical officer, he is a leader within EY physician enterprise operations and clinical integration practice where he assists health care system clients in physician engagement and alignment, provider accountability for value delivery, and defining and maximizing physician enterprise value for health care systems. He has supported organizations as they transition to integrated service line models of care delivery and recognizes the medical group’s impact on driving clinical quality initiatives.

He is a former structural heart cardiologist and senior vice president of heart and vascular services at a 15-hospital integrated regional health care system in the southeast USA. His responsibilities included governance of an enterprise-wide clinical strategy overseeing cardiovascular service line vision, growth, clinical integration, physician alignment and standardization of clinical, operational and business processes.

He obtained his doctor of medicine from the University College Hospital, Nigeria. He trained in internal medicine and cardiology at the College of Physicians and Surgeons of Columbia University and in invasive and interventional cardiology at Cornell University and University of Massachusetts Medical Center. He is board certified by the Canadian Board of Internal Medicine and is triple-board certified in internal medicine, cardiology and interventional cardiology by the American Board of Internal Medicine.

Gil Bashe

Managing Partner, Global Health

Finn Partners

Gil Bashe’s healthcare career spans the patient, physician, provider, payer and policy sectors. At the center of Gil’s life and work is the belief that communication is part of the care. As managing partner of Finn Partners Global Health, he champions the talent and ideas of the nation’s “Healthcare Agency of the Year” (Holmes Report).

Prior to joining Finn Partners, Gil was Executive Vice President and Health Practice Head at Makovsky and Hill & Knowlton. During his tenure, he took on some of the health sector’s most vexing reimbursement and access challenges. As a result, he was named by PRNews as one of the nation’s “Top Crisis Communicators” and inducted into its Hall of Fame.

Gil is passionate about public health in everything he does. He serves on the NHLBI GENTAC Working Group examining how genetics impacts cardiovascular disease and the health/tech advisory committee for mHealth Israel. He is immediate past chair of the American Heart Association Northeast Founder’s Affiliate.

Gil is also an advisory board member of the Prix Galien Foundation, referred to as the Nobel Prize for health innovation. Gil is a past national board member of the Leukemia and Lymphoma Society and American Academy of Pain Medicine Foundation. Always ready to share knowledge, Gil is a columnist for PM360 magazine, speaker on patient advocacy and health communications and co-editor of the book Branding Health Services: Defining Yourself in the Marketplace.

See omnystudio.com/listener for privacy information.

CDC Proclaims Racism Public Health Crisis, Calls for Health Equity

A new mandate out of the Centers for Disease Control & Prevention has asserted systemic racism as a public health crisis, a step the agency says will build the foundation to improve health equity.

The statement from CDC’s director Rochelle P. Walensky, MD, MPH, acknowledged the racial health disparities seen in traditionally marginalized communities, including the Black, Latinx, and American Indian/Alaska Native (AI/AN) populations.

“Yet, the disparities seen over the past year were not a result of COVID-19,” Walensky said in the written statement. “Instead, the pandemic illuminated inequities that have existed for generations and revealed for all of America a known, but often unaddressed, epidemic impacting public health: racism.”

Guests: 

Yele Aluko, MD, MBA

Chief Medical Officer

EY Americas

Dr. Yele Aluko is the chief medical officer in EY Americas Business Consulting Health Sector. He is a proven physician executive and leader, with 25 years of clinical and administrative health system experience prior to joining Ernst & Young LLP in 2016. He advises health system clients on strategy, business and clinical operations providing C-Suite executives insight on health industry megatrends and enterprise growth opportunities. He is a member of the EY COVID-19 Pandemic Response Team where he advises EY leadership on return-to-workplace strategies that prioritize the health and safety of its employees. As a member of the EY COVID-19 Enterprise Resiliency Team, he provides client insight on return-to-work strategies and solutions designed to preserve workforce well-being and safety during and in the aftermath of COVID-19. He is a leader in the development of the EY Point of View on Health Equity and has designed solutions for clients seeking competencies relevant to elimination of health disparities and achieving health equity.

As chief medical officer, he is a leader within EY physician enterprise operations and clinical integration practice where he assists health care system clients in physician engagement and alignment, provider accountability for value delivery, and defining and maximizing physician enterprise value for health care systems. He has supported organizations as they transition to integrated service line models of care delivery and recognizes the medical group’s impact on driving clinical quality initiatives.

He is a former structural heart cardiologist and senior vice president of heart and vascular services at a 15-hospital integrated regional health care system in the southeast USA. His responsibilities included governance of an enterprise-wide clinical strategy overseeing cardiovascular service line vision, growth, clinical integration, physician alignment and standardization of clinical, operational and business processes.

He obtained his doctor of medicine from the University College Hospital, Nigeria. He trained in internal medicine and cardiology at the College of Physicians and Surgeons of Columbia University and in invasive and interventional cardiology at Cornell University and University of Massachusetts Medical Center. He is board certified by the Canadian Board of Internal Medicine and is triple-board certified in internal medicine, cardiology and interventional cardiology by the American Board of Internal Medicine.

Gil Bashe

Managing Partner, Global Health

Finn Partners

Gil Bashe’s healthcare career spans the patient, physician, provider, payer and policy sectors. At the center of Gil’s life and work is the belief that communication is part of the care. As managing partner of Finn Partners Global Health, he champions the talent and ideas of the nation’s “Healthcare Agency of the Year” (Holmes Report).

Prior to joining Finn Partners, Gil was Executive Vice President and Health Practice Head at Makovsky and Hill & Knowlton. During his tenure, he took on some of the health sector’s most vexing reimbursement and access challenges. As a result, he was named by PRNews as one of the nation’s “Top Crisis Communicators” and inducted into its Hall of Fame.

Gil is passionate about public health in everything he does. He serves on the NHLBI GENTAC Working Group examining how genetics impacts cardiovascular disease and the health/tech advisory committee for mHealth Israel. He is immediate past chair of the American Heart Association Northeast Founder’s Affiliate.

Gil is also an advisory board member of the Prix Galien Foundation, referred to as the Nobel Prize for health innovation. Gil is a past national board member of the Leukemia and Lymphoma Society and American Academy of Pain Medicine Foundation. Always ready to share knowledge, Gil is a columnist for PM360 magazine, speaker on patient advocacy and health communications and co-editor of the book Branding Health Services: Defining Yourself in the Marketplace.

See omnystudio.com/listener for privacy information.

Alzheimer's Disease and Related Dementias are a terrible disease on individuals, caregivers, and communities. There are no cures. However, new data has come out discussing the risk factors, polypharmacy, and a potential early detection opportunity. It's time to de-prescribe and follow the money.

Reference: Nicholas LH, Langa KM, Bynum JPW, Hsu JW. Financial Presentation of Alzheimer Disease and Related Dementias. JAMA Intern Med. 2021;181(2):220–227. doi:10.1001/jamainternmed.2020.6432

Maust DT, Strominger J, Kim HM, et al. Prevalence of Central Nervous System–Active Polypharmacy Among Older Adults With Dementia in the US. JAMA. 2021;325(10):952–961. doi:10.1001/jama.2021.1195

CPE details for GameChangers Podcast April 2021

Learning Objective: Discuss if adverse financial outcomes may be a risk factor for future dementia diagnosis.

0107-0000-21-158-H01-P

0.2 CEU/2 Hrs (Knowledge)

Initial Release Date: 04/06/21

Expiration Date: 03/02/24

Additional CPE information is located at https://www.ceimpact.com/podcast 

Disclosure: Dr. Galdo is a member of the Board of Directors for the Alabama Chapter of the Alzheimer's Association.

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Alzheimer's Disease and Related Dementias are a terrible disease on individuals, caregivers, and communities. There are no cures. However, new data has come out discussing the risk factors, polypharmacy, and a potential early detection opportunity. It's time to de-prescribe and follow the money.

Reference: Nicholas LH, Langa KM, Bynum JPW, Hsu JW. Financial Presentation of Alzheimer Disease and Related Dementias. JAMA Intern Med. 2021;181(2):220–227. doi:10.1001/jamainternmed.2020.6432

Maust DT, Strominger J, Kim HM, et al. Prevalence of Central Nervous System–Active Polypharmacy Among Older Adults With Dementia in the US. JAMA. 2021;325(10):952–961. doi:10.1001/jama.2021.1195

CPE details for GameChangers Podcast April 2021

Learning Objective: Discuss if adverse financial outcomes may be a risk factor for future dementia diagnosis.

0107-0000-21-158-H01-P

0.2 CEU/2 Hrs (Knowledge)

Initial Release Date: 04/06/21

Expiration Date: 03/02/24

Additional CPE information is located at https://www.ceimpact.com/podcast 

Disclosure: Dr. Galdo is a member of the Board of Directors for the Alabama Chapter of the Alzheimer's Association.

See omnystudio.com/listener for privacy information.

Episode 21: Sandra Leal

Sandra Leal, the 166th president of the American Pharmacists Association, was powerfully influenced by her childhood experiences growing up in an Arizona border town – including the pharmacist in nearby Mexico who essentially served as her family’s main health care provider.

In this episode, we talk about those formative experiences, and discuss the twin issues dominating pharmacy today: the pandemic, and structural racism in pharmacy. Recorded April 2, 2021.

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices